Lupin Limited – FDA 483, Apr 7, 2017
An FDA inspection of Lupin Limited in Verna, India, revealed significant deficiencies across its quality control, production, and process control systems. The firm failed to thoroughly investigate out-of-specification results, often invalidating them without scientific justification or adequate corrective actions. Additionally, the inspection found inadequate procedures for hold time studies, process validation, and monitoring of manufacturing processes, including issues with data integrity in in-process testing.
ID · a2721371-e28c-4093-bd85-0657e5aed2a8
Full citation text and observation details available on the Dashboard.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.